SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the company for a potential licensing deal.Per the article, AstraZeneca is considering a deal worth up to $15 billion for Summit...